-
-
-
-
-
-
-
Gilead Sciences completes $3.15 billion Tubulis acquisition
-
-
-
-
-
-
-
Gilead extends Arcellx tender offer after clearing regulatory hurdles
-
-
-
-
-
-
-
Gilead to acquire Tubulis for up to $5 billion to expand cancer pipeline
-
-
-
-
-
-
-
Goldman Sachs: 'we expect GILD to continue to engage in strategic BD'
-
-
-
-
-
-
-
UBS Reiterates Buy Rating on Gilead Sciences (GILD) Following ACLX Acquisition Announcement
-
-
-
-
-
-
-
Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options
-
-
-
-
-
-
-
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
-
1,171,061 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

